Alderley Park, UK – 16 October 2019
Diabetes is the number 1 cause of blindness, kidney failure, lower limb amputation and increases your risk of having a heart attack or stroke by a factor of 3.
It affects over 10% of the world’s population.
For those delivering healthcare, their main issue is the escalating costs (over $600B) and 80% of these costs are due to the complications of diabetes.
For those with diabetes, their major worry is also about complications they do not want to hear that their diabetes has now gone on to affect their eyes, kidneys or feet.
There are over 6,000 apps in this space, these are diary tracking apps or companion apps linked to pumps and meters and very few of these have any sort of clinical evidence to support them.
The need and gaping hole in the market is around helping people reduce the risk of developing complications and also integrating the system into the diabetes pathway in a way that saves money – and to prove this clinically.
This is why we have developed intellin
We have a unique technology
Connected to multiple Bluetooth devices to ensure accurate data uploads and ease of use.
We plan to connect the platform to the electronic health record so that an individual’s health information is pre-populated into the platform.
We have unique applications of data
Patients can also refer themselves to third parties to have a consultation about their diabetes.
We have developed algorithms that take an individual’s clinical history and then predict their risk of developing complications, we then provide them with clinically validated hints and tips to prevent these complications.
We have developed intellin with healthcare professionals and people with diabetes to improve the current pathway and empower patients to better manage their disease. We will save money for healthcare providers and help fewer people hear that their diabetes has now gone on to damage their eyes, kidneys or feet.
We have a strong team with a proven track record in diabetes and the pharmaceutical sector and we are using this to create the evidence for intellin with clinical trials and a pilot study.
This summer Gendius completed a £520,000 raise on Crowdcube to expand the team to develop chargeable content for users. In addition, they have been selected as one of fifteen companies in this year’s cohort for the Greater Manchester Future Health Accelerator by UP Ventures and Novartis.